Michael J. Buie- Master of Science
- Medical Student at University of Calgary
Michael J. Buie
- Master of Science
- Medical Student at University of Calgary
IBD Epidemiology Researcher
About
36
Publications
3,282
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
691
Citations
Introduction
Current institution
Publications
Publications (36)
Background & aims:
Acute pancreatitis is a common disease with significant associated morbidity and mortality. We performed a systematic review and meta-analysis of population-based studies to explore the changing temporal trends of acute pancreatitis incidence globally.
Methods:
We performed a systematic literature search to identify population...
Background and Aims
The evolving epidemiologic patterns of inflammatory bowel disease (IBD) throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD. We performed a systematic review with temporal analysis of hospitalization rates for IBD across the world in the 21st century.
Methods...
Background:
Recent advances in the management of inflammatory bowel disease (IBD) striving for new treatment targets may have decreased rates of hospitalization for flares. We compared all-cause, IBD-related, and non-IBD-related hospitalizations while accounting for the rising prevalence of IBD.
Methods:
Population-based, administrative health c...
During the twentieth century, inflammatory bowel disease (IBD) was considered a disease of early industrialized regions in North America, Europe and Oceania¹. At the turn of the twenty-first century, IBD incidence increased in newly industrialized and emerging regions in Africa, Asia and Latin America, while the prevalence in early industrialized r...
Background
The global incidence of appendicitis in 2019 was estimated at 228 per 100,000 person-years. However, temporal trends of appendicitis rates vary between early industrialized and newly industrialized regions.
Aims
To analyze annual appendectomy rates in regions of the Organisation for Economic Co-operation and Development (OECD) in the 21...
BACKGROUND
Rising incidence and prevalence of inflammatory bowel disease (IBD) observed historically in early-industrialized regions now also appear in newly-industrialized and emerging regions. The epidemiology of IBD has been proposed to progress across epidemiologic stages: 1. Emergence (low incidence and prevalence); 2. Acceleration in Incidenc...
BACKGROUND
A theoretical framework for population-level transition across four epidemiologic stages has been proposed for inflammatory bowel disease (IBD): 1. Emergence (low incidence/prevalence); 2. Acceleration in Incidence (rapid rising incidence); 3. Compounding Prevalence (stabilizing incidence, rapid rising prevalence); and 4. Prevalence Equi...
BACKGROUND
Epidemiologic stages of inflammatory bowel disease (IBD) have been proposed: 1. Emergence (low incidence and prevalence); 2. Acceleration in Incidence (rapidly rising incidence, low prevalence); and 3. Compounding Prevalence (stabilizing incidence, rapidly rising prevalence). To date, these stages have been theoretical without quantified...
During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions starte...
Background
Adequate serological responses following two-dose regimens and additional doses of SARS-CoV-2 vaccination have been demonstrated for the vast majority of those with IBD. However, antibody levels following 2nd, 3rd, and 4th dose SARS-CoV-2 vaccination may decrease over time in the IBD population.
Purpose
We assessed the durability of ser...
BACKGROUND
The management of inflammatory bowel disease (IBD) is associated with considerable healthcare and societal cost. A key driver of direct medical cost, remains surgery. Although the cumulative risks of surgery have been well described in countries of the Western world, surgical risk data from Asia, where IBD is rapidly emerging, is lacking...
BACKGROUND
The immune response of SARS-CoV-2 vaccines is uncertain in those with Inflammatory Bowel Disease (IBD) due to a diverse array of immune-modifying therapies that vary in the mechanism of immunosuppression.
AIM
We aimed to quantify the serological response to SARS-CoV-2 vaccines in those with IBD and determine antibody levels across varyi...
INTRODUCTION
The evolving epidemiologic patterns of IBD throughout the world, in conjunction with advances in therapeutic treatments, may influence hospitalization rates of IBD in the 21st century. We performed a systematic review with temporal analysis of hospitalization rates for IBD across the world in the 21st century.
METHODS
We systematicall...
Background
Acute pancreatitis is a common disease with significant associated morbidity and mortality. Historically, acute pancreatitis has been considered a disease with multiple etiologies and risk factors but is driven by alcohol and biliary disease. Multiple studies have shown that the incidence of acute pancreatitis is increasing globally amon...
Background
Inflammatory bowel disease (IBD) first presents in a population as cases of ulcerative colitis (UC) followed by cases of Crohn’s disease (CD). Newly industrialized countries (NIC) show a prallel epidemiology of IBD to highly industrialized countries (HIC) in the previous century; one marker of this is the relative incidence/prevalence ra...
Background
Prevalence of inflammatory bowel disease (IBD) exceeds 0.3% in N. America, Europe, and Oceania, but many Westernized nations report decreasing hospitalization rates (HR) following the advent of biologics. However, IBD incidence is rapidly rising in newly industrialized countries in Asia and S. America, which may correspond to increasing...
Background
The prevalence of the inflammatory bowel diseases (IBD), consisting of Crohn’s disease and ulcerative colitis, now exceeds 0.3% in North America, Europe, and Oceania, and has been reported as high as 0.7% in some nations within those regions. Conversely, in newly industrialized countries in South America, the Middle East, and Asia, both...
